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ABSTRACT
Gastric cancer is the third leading cause of cancer mortality worldwide. As 
surgery is the only curative treatment strategy and conventional chemotherapy has 
shown limited efficacy -with a median overall survival of 10 months- new treatments 
are urgently needed. Trastuzumab and Ramucirumab (targeting HER2 and VEGFR2, 
respectively) are the only targeted therapies approved so far. Indeed, most Phase 
III clinical trials evaluating molecular drugs in gastric cancer failed. This review 
will retrace the relevant clinical trials with molecular therapies performed in gastric 
cancer patients, discussing the possible reasons for their failure and indicating new 
perspective for a real improvement of the treatment of this disease.
INTRODUCTION
Gastric cancer is the third leading cause of global 
cancer-related deaths worldwide [1], with approximately 
one million new cases diagnosed each year. In spite 
of the significant advances in surgical techniques, 
improvements in diagnosis and development of new 
chemotherapy protocols, the overall clinical outcome for 
patients with advanced gastric cancer is poor, with 5-20% 
5-year survival and 10 months median overall survival 
(OS) [2]. Incidence is strongly influenced by ethnical 
and geographical factors, and it is higher in Eastern 
Asia, Eastern Europe, and South America, while North 
America and Africa show the lowest recorded rates [3]. 
About 80-90% of gastric carcinomas develop in a sporadic 
setting, the remaining 10% to 20% show familial cluster, 
and approximately 1-3% have a clear inherited genetic 
susceptibility [4]. 
Two main classifications are in use to define gastric 
adenocarcinomas. The WHO (World Health Organization) 
classification describes four histological subtypes 
(papillary, tubular, mucinous and poorly cohesive) while 
Lauren’s classification identifies intestinal, diffuse, or 
mixed subtypes [5]. However, these two classifications 
do not have a prognostic value and cannot help guide 
the therapeutic approach. Very recently, two wide 
molecular classifications have been published (Table 1). 
The Cancer Genome Atlas Group identified four major 
molecular subtypes [6]: i) the most frequent (around 50% 
of tumors) is characterized by chromosomal instability 
(CIN) and amplification of genes, mainly encoding 
tyrosine kinase receptors; ii) tumors with Microsatellite 
Instability (MSI, 22%), presenting a very high mutation 
rate and DNA methylation; iii) genomically stable (20%) 
tumors and iv) Epstein Barr Virus positive tumors (9%), 
characterized by DNA hypermethylation, high frequency 
of PIK3CA mutations and PDL1/PDL2 overexpression. 
Even if this classification has no prognostic value, as no 
survival difference was found among the four subgroups, 
it represents a milestone for the identification of new 
molecular targets and the design of new therapeutic 
approaches. 
A new gastric cancer classification based on 
molecular characteristics was provided also by the Asian 
Cancer Research Group [7]. They also identified a MSI 
group, while the MSS (Microsatellite Stable) tumors 
were subdivided on the basis of evidence of epithelial-
mesenchymal transition (EMT), presence of wild type 
TP53 or TP53 inactivation. Interestingly, these molecular 
subtypes were associated with clinical parameters. The 
MSS/EMT was characterized by the worst prognosis and 
a higher chance of recurrence, while the MSI subtype 
showed the best prognosis. 
Altogether, these two classifications represent 
a critical forward step in our understanding of the 
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molecular basis of gastric cancer and can be crucial 
to develop rational molecular therapies to improve 
the outcome of these patients. For the moment, in fact, 
the main therapeutic options rely on surgery and the 
use of cytotoxic drugs such as platinum-based agents, 
irinotecan and taxanes. Differently from other tumors 
where many therapeutic options are available on the 
basis of the molecular characteristics of the tumor, only 
two target therapies have been approved by FDA (Food 
and Drug Administration, USA) and European Union for 
advanced gastric cancer (Trastuzumab -October 2010- and 
Ramucirumab -December 2014) but most of the patients, 
at the moment, do not get a benefit from them.
Table 1: Molecular Classifications of Gastric Cancer proposed by The Cancer Genome Atlas and the Asian Cancer 
Research Group.
TCGA  (The Cancer Genome Atlas) ACRG (Asian Cancer Research Group)  
SUBTYPES MOLECULAR FEATURES SUBTYPES MOLECULAR FEATURES
 EBV
 (9%)
-DNA hypermethylation 
-high frequency of PIK3CA mutations 
-PDL1/PDL2 overexpression
MSS/TP53+ (26%) -frequent  EBV positivity-intermediate mutation rate 
MSI 
(22%)
-high mutation rate 
-DNA methylation
MSI
 (23%) -high mutation rate 
GS
 (20%)
-molecular alterations in cell adhesion/ 
cell migration pathways
 -ARID1 and BCOR mutations
EMT
 (15%)
-low mutation rate
-loss of epithelial markers
CIN
 (50%)
- chromosomal instability (CIN)
-amplification of genes (most encoding 
tyrosine kinase receptors)
MSS/TP53- 
(36%)
-TP53 mutations
-genomic instability 
EBV = Epstein Barr Virus; MSI = Micro Satellite Instable; MSS = Micro Satellite Stable; EMT = Epithelial Mesenchymal 
Transition; GS = Genomically Stable; CIN = Chromosomal Instability.
Figure 1: The HER family of Receptor Tyrosine Kinases. Schematic illustration of the receptors of this family, their ligands and 
their major downstream signal transducers.
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HER2 IN GASTRIC CANCER
The HER2 receptor is a member of the Epidermal 
Growth Factor Receptor (EGFR) family, with the 
unique property of lacking a high affinity specific ligand 
(Figure 1). Its activation is due to its spontaneous homo/
heterodimerization with the other EGFR family receptors, 
of which it is the preferred dimerization partner [8]. HER2 
is amplified in different tumors, such as breast, pancreatic, 
colorectal and gastric cancer [9]. In particular, in breast 
and colon cancer, HER2 amplification correlates with 
response to anti-HER2 drugs [10]. 
Several studies showed HER2 overexpression and 
amplification in gastric cancer, but due to difference in 
the examination methods, the frequency of positivity is 
considerably different in the diverse studies, ranging 
from 6% to 30% [11-19]. Notably, gastric cancer 
frequently shows heterogeneity of the HER2 genotype 
and phenotype that can be partially responsible for testing 
inaccuracy [20]. HER2 testing in gastric cancer reveals 
important differences compared to breast cancer: i) in 
breast, full membrane staining is mandatory for 2+/3+ 
evaluation, while in gastric cancer lateral or basal staining 
is sufficient; ii) differently from breast cancer, gastric 
cancer often stains heterogeneously; thereof, a threshold 
of 10% positive cells was considered appropriate to 
assess HER2 status (30% for breast tumors). Despite this 
consensus, discordances are still present concerning the 
best criteria to determine HER2 positivity. In fact, while 
EMEA (European Medicines Agency) has recommended 
IHC (immunohistochemistry) as initial screening, with 3+ 
samples considered positive and 2+ positive if confirmed 
by FISH (Fluorescence in situ hybridization) analysis 
(Annex I. Summary of product characteristics. European 
Medicines Agency; 2010), FDA recommended selection 
of either 3+ or FISH+ patients. In light of the relatively 
high frequency of overexpression/amplification of HER2 
in gastric cancer, preclinical and early phase clinical 
studies have been performed to evaluate the therapeutic 
potential of its targeting in this context [10, 21, 22]. Phase 
II trials [23, 24] provided the rationale for the ToGA study, 
evaluating Trastuzumab plus chemotherapy (capecitabine, 
cisplatin) versus chemotherapy alone in HER2+ advanced 
gastric/gastroesophageal patients [25] (Figure 2). The 
investigators analyzed patients through both IHC and 
FISH and randomized 594 HER2+ cases; less than 
Figure 2: HER2 as a target in gastric cancer. Schematic illustration of the HER2 receptor and of the targeted drugs tested in clinical 
trials (the mAbs Pertuzumab and Trastuzumab -and its emtansine conjugated, T-DM1- and the dual HER1/HER2 small kinase inhibitor 
Lapatinib). The insert table shows the major trials targeting HER2. PFS = Progression Free Survival; OS = Overall Survival.
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half of them were classified as FISH positive, IHC 3+. 
Overall survival, the primary endpoint of the study, was 
significantly longer in patients receiving Trastuzumab plus 
chemotherapy (13·8 months vs 11·1; HR: 0·74; 95% CI 
0·60-0·91). Progression free survival (6·7 vs 5·5 months), 
overall response rate (47% vs 35%) and the duration 
of response (6·9 vs 4·8 months) were increased as well 
in patients receiving Trastuzumab. Subgroup analysis 
showed that OS was significantly extended in patients 
with higher HER2 expression (IHC 3+ or IHC 2+/FISH 
positive) treated with Trastuzumab (16 vs 11.8 months). 
Conversely, in 131 patients with low HER2 expression, 
the addition of Trastuzumab did not improve survival. 
Altogether these results suggest that Trastuzumab provides 
the best therapeutic benefit to strongly HER2+ patients. 
Similar results have been recently obtained in the non-
interventional study HERMES [26].
Although the results of the ToGA trial led to the 
approval of Trastuzumab in HER2+ metastatic gastric 
patients, there are still open questions. It is not clear if 
the addition of Trastuzumab to standard chemotherapy is 
effective in the adjuvant setting after previous gastrectomy 
as the 133 patients falling in this category did not show 
statistical improvement when treated with Trastuzumab. 
It is not clear as well if patients with locally advanced 
disease could benefit from this therapy, as only 20 of them 
were analyzed and no improvement was observed upon 
Trastuzumab. Finally, no stratification was done according 
to the site of gastric origin or the pathology of the disease, 
so it is unclear if these factors have predictive value. 
In light of the new knowledge, it will be interesting to 
evaluate if patients with HER2 amplification of the EBV 
subtype behave as those of the CIN subtype and if patients 
with HER2 mutations, found mainly in the MSI subtype, 
are also responsive to the treatment. 
Another open question is the opportunity to continue 
Trastuzumab in second line therapy beyond progression. 
To evaluate this point in gastric cancer patients a study was 
retrospectively performed in patients progressed after first-
line Trastuzumab-based chemotherapy [27]. Thirty two 
HER2+ gastric cancer patients (IHC 3+ or IHC 2+/FISH+) 
received fluoropyrimidine-, platinum- and Trastuzumab-
containing regimens as first-line therapy and irinotecan 
or taxanes with or without Trastuzumab as second-line 
therapy. No significant difference in PFS (median, 3·6 
vs. 2·8 months) and OS (median, 9·5 vs. 7·6 months) 
was observed between the two cohorts, while marginal 
improvements in PFS (median, 4·4 vs. 2·1 months) and 
OS (median, 7·8 vs. 6·7 months) were observed when 
confined to the IHC 3+ subgroup. Larger prospective 
trials are required to definitely prove that continuing 
Trastuzumab monotherapy until disease progression could 
extend overall survival in these patients. 
Recently, T-DM1, which combines Trastuzumab 
with the anti-microtubule agent emtansine, has been 
approved for HER2+ breast cancer. Preclinical works 
have shown that T-DM1 is active in gastric cancer models 
[28, 29]. Unfortunately, a randomized, open-label, phase 
II/III study of T-DM1 versus a taxane in patients with 
previously treated HER2+ locally advanced or metastatic 
gastroesophageal tumors (GATSBY) did not show efficacy 
benefit over taxanes [30]. The reasons of this negative 
result are not clear. As expected, T-DM1 performed better 
in HER2 IHC3+ patients than in negative ones. However, 
almost no difference in outcome was observed in patients 
previously treated with HER2-targeted therapies vs. naïve 
patients. Thus, it is unlikely that a problem of resistance 
due to previous treatments can justify the negative results. 
A possible explanation is that systemic chemotherapy 
plus Trastuzumab performs better than T-DM1 because 
the former can take care also of low-level/HER2- clones. 
Alternatively, or in addition, as it up to 35% of gastric 
tumors lost their HER2+ status after I line therapy, a 
decreased level of HER2 could impair the activity of 
T-DM1 but not that of taxanes. Lapatinib is a dual EGFR/
HER2 small kinase inhibitor approved for treatment of 
HER2+, locally advanced or metastatic breast cancer 
[31]. The Southwest Oncology Group performed a 
phase II trial of Lapatinib as first line therapy in patients 
with advanced or metastatic gastric cancer [32]. The 
study (47 patients not selected for HER2 amplification) 
showed only a modest single-agent activity. The LOGIC 
trial, a double-blinded study, investigated Lapatinib 
in combination with capecitabine plus oxaliplatin in 
HER2+ advanced or metastatic first line gastroesophageal 
carcinoma patients [33]. The addition of Lapatinib did 
not significantly increase OS. A phase III study (TyTAN) 
was performed in HER2 amplified advanced gastric 
cancer Asian patients, treated with paclitaxel alone or in 
association with Lapatinib in second line [34]. Median 
OS was 11·0 months with Lapatinib plus paclitaxel versus 
8·9 months with paclitaxel alone (P = 0·1044), with no 
significant difference in median PFS (5·4 vs 4·4 months) 
or TTP (5·5 vs 4·4 months). Better efficacy with Lapatinib 
plus paclitaxel was demonstrated in IHC 3+ patients. 
Overall, Lapatinib plus paclitaxel demonstrated activity 
in second-line treatment but did not significantly improve 
OS. Very recently, Lorenzen et al. conducted a phase II 
trial in which 37 pts were randomized to Lapatinib plus 
capecitabine or capecitabine alone but the study was 
closed prematurely for futility [35]. Overall, these studies 
suggest that Lapatinib, as single targeted therapy, is poorly 
active in gastric cancer. One possible explanation for the 
different effect of Trastuzumab and Lapatinib in gastric 
cancer patients might rely on the contribution of antibody-
dependent cell-mediated cytotoxicity (ADCC), lacking in 
the small molecule therapeutic approach. Further studies 
are needed to evaluate if, as shown in preclinical setting 
[36], it synergizes with Trastuzumab.
Pertuzumab is a HER2 monoclonal antibody that 
interferes with HER2 heterodimerization with other 
EGFR family members. As it is effective in HER2+ breast 
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cancer patients in combination with Trastuzumab [37], 
a phase III trial (JACOB) is ongoing, in which HER2+ 
metastatic gastric cancer patients will receive Pertuzumab 
or placebo, in combination with Trastuzumab and 
chemotherapy. Randomization will be stratified by region, 
prior gastrectomy, and HER2-positivity (IHC 3+ vs IHC 
2+ and ISH+ [in situ hybridization]). 
Altogether, these results suggest that HER2 is 
a good target in gastric cancer even though the criteria 
to select patients that could benefit from therapy should 
be better defined. As suggested by Gomez-Martin and 
colleagues, it is likely that a real “addiction” of cancer 
cells to HER2 and response to anti-HER2 therapies require 
a level of amplification of around 10 copies, with a better 
response in patients showing higher levels of amplification 
[38]. Moreover, it has yet to be defined which is the best 
therapeutic strategy as the response to anti-HER2 drugs is 
somehow “organ specific”; in fact, while Trastuzumab is 
effective in monotherapy in breast cancer, this is not true in 
HER2-amplified colon cancer, as demonstrated in Patient-
Derived Xenografts (PDXs) preclinical models [39]. 
However, treatment against HER2 proved to be effective 
in colorectal cancer patients by using the combination of 
Trastuzumab and Lapatinib [40]. It will thus be important 
to determine the best therapeutic approach in gastric 
patients. 
EPIDERMAL GROWTH FACTOR 
RECEPTOR
The Epidermal Growth Factor Receptor is amplified 
in around 5% of gastric cancers, characterized by poor 
prognosis [6]. Two phase III studies have investigated the 
efficacy of Cetuximab in association with chemotherapy 
(Figure 3). The EXPAND trial, evaluating capecitabine 
and cisplatin with or without Cetuximab in patients with 
previously untreated tumors, did not observe any benefit 
with the addition of Cetuximab [41]. The REAL3 trial, 
studying epirubicin, oxaliplatin and capecitabine with 
or without Panitumumab in first line reached similar 
results [42]. The major problem of these two studies is 
that no patient selection was done on the basis of EGFR 
amplification/overexpression. This renders the results 
quite questionable. In fact, while in colon cancer the 
EGFR status is not usually analyzed as the wild type 
receptor activity is considered critical for tumor growth, 
no such data are available in gastric cancer. Experimental 
data, indeed, have shown a positive correlation between 
Figure 3: HER1 (EGFR) as a target in gastric cancer. Schematic illustration of the EGFR receptor and of the targeted drugs tested 
in clinical trials (the mAbs Cetuximab, Panitumumab and Nimotuzumab). The insert table shows the major trials targeting EGFR. PFS = 
Progression Free Survival; OS = Overall Survival.
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Cetuximab response and EGFR high expression/
amplification [43]. On this line are the results of a phase 
II trial assessing Cetuximab plus oxaliplatin/leucovorin/5-
fluorouracil, showing an association between higher 
EGFR copy number (≥4) and OS [44]. In addition, trials 
of novel EGFR agents are ongoing. Of note, the phase III 
ENRICH trial of irinotecan with or without Nimotuzumab 
in preselected patients with high EGFR expression. 
Overall, before disregarding EGFR as a possible 
target in gastric cancer, we should carefully identify 
patients with EGFR pathway activation and evaluate the 
effect of inhibition of this receptor in this context. 
HEPATOCYTE GROWTH FACTOR/
HEPATOCYTE GROWTH FACTOR 
RECEPTOR
The most frequent genetic alteration of the 
Hepatocyte Growth Factor Receptor (encoded by the 
MET gene) is gene amplification, which is associated with 
shorter survival [45, 46]. 
In the last years, several drugs targeting the MET/
HGF axis have been developed, including monoclonal 
antibodies (directed against either HGF or MET) and 
MET small kinase inhibitors (Figure 4). On the basis 
of a Phase II trial showing a survival advantage from 
the addition of the anti-HGF antibody Rilotumumab to 
chemotherapy, two phase III clinical trials were started 
(RILOMET-1 and RILOMET-2). Unfortunately, both the 
studies have been prematurely closed, due to an increase 
in the number of deaths in the Rilotumumab arms [47, 48]. 
Onartuzumab, a MET antibody, was evaluated in the phase 
III METGastric trial, in combination with mFOLFOX6 
(modified Folinic Acid (Leucovorin)-Fluorouracil-
Oxaliplatin 6), in HER2-/MET+ gastric cancer patients. 
As preliminary results revealed a higher rate of serious 
toxicities in the experimental arm, in particular in high 
MET patients, the trial was stopped [49]. Negative results 
were obtained also in a phase II trial with the multikinase 
MET inhibitor Foretinib, in molecularly unselected 
metastatic patients [50]. In spite of the encouraging pre-
clinical data, the results of most of the trials targeting 
MET in gastric cancer are very disappointing, raising 
doubts about the utility of targeting this oncogene in 
gastric cancer. It is actually possible that MET is not a 
good target in this context. However, there were scattered 
reports of complete and exceptionally durable responses 
Figure 4: The MET/HGF pathway as a target in gastric cancer. Schematic illustration of the MET tyrosine kinase receptor, its 
ligand HGF and the targeted drugs tested in clinical trials (the HGF mAb Rilotumumab, the MET mAb Onartuzumab and the multikinase 
small kinase inhibitor Foretinib). The insert table shows the major trials targeting the MET/HGF pathway. PFS = Progression Free Survival; 
OS = Overall Survival.
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in gastric cancer patients treated with anti-MET antibodies 
[51] or small molecules [52]. In particular, positive results 
were reported from a Phase I Trial with the MET specific 
small molecule AMG 337 (NCT01253707). Among 10 
patients bearing MET-amplified gastric and esophageal 
cancers, one experienced a durable complete response 
(100 weeks), and four displayed a partial response [52]. 
One possible explanation for the trial failures so far could 
be that these trials have not appropriately selected the 
patients that could benefit from the therapy. The MET 
gene is amplified in not more than 4% of gastric cancer 
[6]; moreover, experimental data have shown that tumor 
cells become “addicted” to MET (and thus responsive to 
its inhibition) when they have at least 8 gene copies [53]. 
However, in the studies performed in MET+ patients, 
the selection has usually been conducted on the basis 
of immunohistochemistry, that does not discriminate 
between overexpression and amplification. Notably, MET 
overexpression in the absence of amplification (e.g. as a 
consequence of hypoxia [54]) is extremely frequent in 
cancers. Other possible causes of primary resistance to 
anti MET drugs in gastric cancer are i) coamplification 
of different driver oncogenes, a phenomenon that was 
recently reported to frequently occur in gastro-esophageal 
cancer and ii) the extensive heterogeneity in MET gene 
amplification among distinct tumor lesions within the 
same patient [55]. If this is true, the success of a clinical 
trial with anti-MET compounds would require a much 
stringent selection of the patients, based on genomic data 
on the levels of MET amplification, possibly integrated 
by comprehensive molecular analysis; moreover, since 
the molecular profiling of a single-lesion biopsy may be 
insufficient to guide targeted therapy selection, liquid 
biopsy strategies might help to better select patients that 
could really benefit from MET targeted therapies. Finally, 
very recently, exon 14 skip mutations of MET have been 
found to confer high sensitivity to MET inhibitors [56, 
57]. As such mutations have been identified also in gastric 
cancer patients [58], it will be very important to evaluate 
their sensitivity to MET inhibitors. More work is thus 
required to better identify potentially responsive patients 
and to evaluate the most effective inhibitors. 
Figure 5: The VEGF/VEGFR pathway as a target in gastric cancer. Schematic illustration of VGFR2 (expressed mainly on 
endothelial cells), its ligand VEGF-A, and targeted drugs tested in clinical trials (the VEGF-A mAb Bevacizumab, the VEGFR2 mAb 
Ramucirumab and the VEGFR2 small kinase inhibitor Apatinib). The insert table shows the major trials targeting the VEGF/VEGFR 
pathway. PFS = Progression Free Survival; OS = Overall Survival.
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VASCULAR ENDOTHELIAL GROWTH 
FACTOR/VASCULAR ENDOTHELIAL 
GROWTH FACTOR RECEPTOR
VEGF/VEGFR2-dependent signaling plays an 
important role in tumor angiogenesis. Even though at 
the moment there is no predictive factor for selection of 
patients that could benefit from this therapy, it has been 
reported that in gastric cancer VEGF expression and 
serum levels correlate with more advanced stage disease 
and poor outcome [59]. Moreover, preclinical data have 
shown that VEGFR2 inhibition impaired tumor growth 
and angiogenesis in gastric cancer animal models [60].
Based on promising results of two phase II studies 
[61, 62], a phase III trial comparing chemotherapy with 
or without Bevacizumab (a VEGF-A mAb) in first line 
gastric cancer patients was conducted [63] (Figure 5). The 
results showed a significant improvement in PFS (6·7 vs 
5·3 months) and overall RR (46 vs 37·4%), even though 
the primary endpoint (OS) was not reached. Moreover, the 
study showed important differences between Western and 
Asian patients, the formers benefitting most from the anti-
angiogenic therapy. 
Very recently, two Phase III studies evaluated the 
role of Ramucirumab, a VEGFR-2 mAb interfering with 
VEGFs binding to their receptor. The REGARD study 
evaluated Ramucirumab as second line therapy after 
disease progression on a first line chemotherapy regimen, 
in patients with advanced, unresectable gastroesophageal 
tumors [64]. Median overall survival was 5.2 months in the 
Ramucirumab group and 3.8 months in the placebo group 
(P = 0·047). A longer PFS (2.1 months for Ramucirumab 
vs. 1.3 for placebo) was also reported. Overall, this study 
identified Ramucirumab as the first biological treatment 
given as a single drug showing survival benefits in patients 
with advanced gastro-esophageal adenocarcinomas 
progressed after first-line chemotherapy. A second phase 
III study (RAINBOW) investigated the same antibody in 
association with paclitaxel, as second line treatment in 
patients with metastatic gastric cancer who progressed 
after a first line chemotherapy [65]. Overall survival was 
significantly longer in the Ramucirumab plus paclitaxel 
group than in the placebo group (9.6 vs. 7.4 months). 
Furthermore, Ramucirumab plus paclitaxel significantly 
delayed disease progression (PFS 4.4 vs. 2.9 months) 
and increased response rate (28% vs. 16%). Based on 
these results, Ramucirumab has been approved by FDA 
and the European Commission either as a single agent or 
in association with paclitaxel in patients with advanced 
or metastatic gastric and gastroesophageal junction 
cancer after progression on fluoropirimidine or platinum 
containing regimens. 
In contrast to the refractory setting, the addition 
of Ramucirumab was not superior to chemotherapy 
alone in the first-line setting. Yoon and colleagues, 
in fact, performed a phase II trial, where 168 patients 
were randomized to mFOLFOX6 plus Ramucirumab or 
placebo [66]. Although patients in the investigational arm 
experienced a higher disease control rate (85% vs. 67%), 
no difference was observed in PFS (6.4 vs. 6.7 months) 
and OS (11.7 vs. 11.5 months). 
Among the antiangiogenic agents under 
investigation in gastric cancer is Apatinib, an oral 
VEGFR-2 inhibitor. In a phase III trial, patients progressed 
on second line therapy were randomized to Apatinib or 
placebo. Median OS (140 days with placebo vs. 195 days 
with Apatinib) and PFS (53 vs. 78 days) were significantly 
improved [67]. 
Although anti-angiogenic therapies have obtained 
successful results in big trials such as REGARD and 
RAINBOW, at the moment, for this kind of therapy, 
there are no biomarker predictors of response. It is thus 
impossible to select patients with higher probability of 
response to treatment. The TCGA classification showed 
that the CIN and Genomically Stable subtypes were 
associated with VEGF-A gene amplification and elevated 
expression of angiogenesis-related pathways, respectively. 
Even though these data are now not sufficient to influence 
the therapeutic strategies, they can give hints to select 
patients. 
Another consideration stemming from the performed 
studies is that drugs directed against VEGFR-2 seem to be 
more effective than those targeting VEGF-A. The reason 
of this behavior is not clear but it is possible that during 
tumor evolution neoplastic cells change the expression 
of the VEGF ligands, thus decreasing the response to 
VEGF-A targeting drugs. 
OTHER TARGETS
The Fibroblast Growth Factor 2 receptor tyrosine 
kinase (FGFR-2) is amplified in around 10% of gastric 
tumors, mainly of the CIN subtype [6] and its amplification 
is associated with lymphatic invasion and worse prognosis 
[68]. As preclinical data suggest that FGFR2-amplified 
gastric cancers respond to targeted inhibitors [69], clinical 
trials where patients selected for FGFR2 amplification 
or polisomy are treated with inhibitors such as Dovitinib 
(NCT01719549) or AZD4547 (NCT01457846) are 
ongoing.
The PI3K/AKT/mTOR pathway is very frequently 
altered in human tumors and its activation often sustains 
resistance to targeted therapies. Mutations of PIK3CA 
(the PI3K encoding gene) are present in 24% of gastric 
cancers, being particularly frequent in the EBV and the 
MSI subtypes (72% and 42%, respectively [6]). Moreover, 
mutations of PTEN, a negative controller of the PI3K/
AKT pathway, are present in 11% of the tumors, more 
frequently in the MSI subtype. Even though the activation 
of this pathway is frequent in gastric tumors, a phase III 
study evaluating the mTOR (a downstream effector of the 
pathway) inhibitor Everolimus on patients with advanced 
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Figure 6: Immune checkpoint inhibitory pathways as targets in gastric cancer. Schematic illustration of molecules expressed 
in tumor cells (left part) and T lymphocytes (right part) involved in the immune checkpoint inhibitory pathway and of the targeted drugs (the 
PD-1 mAbs Pembrolizumab and Nivolumab, the CTLA-4 mAb Ipilimumab). The insert table shows the major trials targeting this pathway.
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gastric cancer failed to show improved survival [70]. 
Similarly, a phase II study of MK-2206, an allosteric 
inhibitor of AKT, gave negative results [71]. Notably, in 
neither study enrolled patients were selected for PI3K 
pathway activation. 
Altogether, the results of these trials are not 
conclusive as treatment was not performed in patients 
selected to display mutations of target genes and activation 
of the pathway. More accurate studies are thus required 
to better understand if PI3K/AKT/mTOR are indeed 
“drivers” in some gastric cancer and to define the most 
efficient drugs.
IMMUNOTHERAPY
Several studies have shown that immunotherapy, 
reactivating the immune system against tumor cells, could 
provide a therapeutic advantage in many cancer types 
[72, 73]. Years ago, some studies proved that potentiating 
the immune system with cancer vaccines could provide a 
significant benefit in the adjuvant setting in gastric cancer 
[74]. Further studies showed the therapeutic potential 
of adoptive cell therapy with either tumor infiltrating 
lymphocytes or dendritic cells [75-77]. However, at 
present, the most promising strategy is immune checkpoint 
inhibition (Figure 6). Immune checkpoints (involving 
PD-1 and CTLA-4) are inhibitory pathways crucial for 
maintaining self-tolerance. PD-1 is a checkpoint protein on 
T cells that prevents them from attacking cells expressing 
the PDL1/2 ligands. Monoclonal antibodies that target 
either PD-1 or PD-L1 can abrogate this checkpoint 
inhibition, thus boosting the immune response against 
cancer cells (reviewed in [78]). CTLA-4 (Cytotoxic 
T-Lymphocyte-Associated protein 4, also called CD152) is 
constitutively expressed on Treg cells and upregulated in 
conventional T cells after activation. When bound to CD80 
or CD86 it contributes to T lymphocyte inhibitory function 
[79, 80] Inactivation of these inhibitory checkpoints 
helps cancer cells to maintain an immunosuppressive 
microenvironment. Studies performed in other tumor 
types have shown a remarkable efficacy of drugs targeting 
these pathways such as Pembrolizumab, Nivolumab (PD-1 
mAbs), Avelumab (PDL-1 mAb) and Ipilimumab (CTLA-
4 mAb) (reviewed in [81]). Very recently, these drugs have 
been explored in the contest of gastric cancer as well. The 
phase I KEYNOTE-012 trial investigated Pembrolizumab 
in heavily pretreated patients with either recurrent or 
metastatic tumors of the stomach or the gastro-esophageal 
junction [82]. Only patients with PD-L1 positive tumors 
were enrolled; PD-L1 positivity was assessed with 
immunohistochemistry assays and defined as membrane 
staining in ≥1% of cells, or for the presence of a distinctive 
PD-L1 positive pattern at the interface between neoplastic 
cells and adjacent stroma. Pembrolizumab elicited 
sustained antitumor responses in 22% of patients (8 /39 
patients) by central review, with no significative difference 
in antitumor activity or safety between Asian or non-Asian 
patients. The EBV status of the treated patients was not 
evaluated. Although the data were preliminary, a trend 
toward an association between higher PD-L1 levels and 
ORR, PFS and OS was observed. Currently, new trials are 
investigating the efficacy and safety of Pembrolizumab 
in patients with advanced gastric cancer. In the MK-
3475-059/KEYNOTE-059 Phase II trial (NCT02335411) 
Pembrolizumab will be given as monotherapy to 
participants who have had previous treatment or who are 
treatment-naïve; Pembrolizumab will also be evaluated 
as combination therapy with chemotherapy in treatment-
naïve participants. The randomized, phase III MK-3475-
059/KEYNOTE-061 (NCT02370498) will evaluate 
Pembrolizumab versus paclitaxel in advanced gastric 
cancer patients with tumor progression after first-line 
treatment with platinum and fluoropyrimidine doublet 
therapy. The study hypotheses will primarily evaluate if 
Pembrolizumab prolongs progression free survival and 
overall survival and the possible correlation of response 
with PD-L1 expression. The randomized, phase III MK-
3475-059/KEYNOTE-062 trial (NCT02494583) will 
compare the activity of Pembrolizumab as monotherapy, 
or Pembrolizumab plus dual chemotherapy, or placebo 
plus dual chemotherapy, in gastric cancer patients with 
PD-L1 positive tumors. 
Another Phase III trial (NCT02267343), not 
limiting patient enrollment by PD-L1 biomarker status, 
was initiated in October 2014 to compare Nivolumab 
versus placebo in previously treated Japanese patients 
with unresectable advanced or recurrent cancer. 
Finally, the randomized, phase III, CheckMate649 
trial (NCT02872116) will compare the efficacy of the 
combination Nivolumab plus Ipilimumab against the 
chemotherapy standard in gastric cancer patients. Overall 
survival will be analyzed in all randomized subjects and 
in subjects with PD-L1 expressing tumors. Initials results 
for the Phase I/II CheckMate-032 study of Nivolumab 
monotherapy in advanced and metastatic gastroesophageal 
cancer patients demonstrated encouraging antitumor 
activity in heavily pretreated patients (overall response 
rate 12%: 1 complete response and 6 partial responses; 
21% stable disease), regardless from PD-L1 expression 
[83]. In a Phase Ib study (NCT01772004), Avelumab 
showed promising clinical activity in unselected patients 
treated as first-line maintenance or second-line therapy 
[84], thus supporting the opening of two randomized 
Phase III trials. Negative results were instead obtained in 
a Phase II trial (NCT01585987) with Ipilimumab that was 
stopped post-interim analysis as no difference in immune-
related progression free survival was observed versus best 
supportive care [85]. Finally, with the idea to combine 
immunotherapy and targeted therapy, two multicenter 
phase IB/II studies are determining antitumor activity and 
safety of Pembrolizumab in combination with anti-HER2 
agents in patients with HER2 positive gastric cancer 
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(NCT02901301 and NCT02689284).
The available data are certainly at an early stage, but 
the high response rates and preliminary OS data justify the 
excitement associated with PD-1 inhibitors and add gastric 
cancer to the growing list of tumors in which immuno-
oncology may play a significant role. The molecular 
profiling from the TCGA identified elevated PD-L1 
expression in the EBV gastric cancer subtype. Although 
there is no agreement that an increased expression of 
PD-L1/PD1 is strictly required to obtain a response with 
the immune checkpoint drugs, it will be interesting to 
investigate the efficacy of immunotherapy in this subtype 
of patients. Even more interestingly, will be the evaluation 
of immunotherapy in patients displaying microsatellite 
instability. Indeed, a recent work performed on colon 
cancer showed that the mismatch-repair deficient status 
predicts clinical benefit of immune checkpoint blockade 
[88], likely increasing the spectrum of neo-antigens able 
to elicit an immune response. As around 20% of gastric 
cancer patients display MSI, they represent a wide 
subpopulation which could benefit from this therapy. 
CONCLUSIONS
Over the past years, many molecular drugs entered 
clinical trials for gastric cancer but, with the exception 
of Trastuzumab and Ramucirumab, all failed. Why did 
it happen? First of all, despite the high prevalence of 
gastric cancer, this tumor has been poorly studied from 
a molecular point of view and only recently few large 
and comprehensive genomic surveys have been reported. 
These studies highlighted several molecular alterations 
in possible driver genes that can thus be considered as 
promising therapeutic targets. Precision medicine has 
clearly shown that patient selection for the molecular 
alteration of the target is mandatory to perform clinical 
trials likely to define the efficacy of the inhibition of a 
given target. In this perspective, the study performed by 
TCGA [6] offers a very powerful instrument to orientate 
the analysis. For example, tumors of the EBV and MSI 
subtype are likely to present PI3K mutations while CIN 
tumors are those displaying the highest frequency of 
receptor tyrosine kinase amplification. 
Another important issue is to define the optimal 
therapy for the identified target. It is now clear that the 
tumor context can modify the response to drugs. For 
example, HER2+ breast cancers respond to Trastuzumab 
monotherapy while HER2+ colon cancers do not [39, 
89]. Moreover, it is not obvious that a mutated gene that 
behaves as a driver in a context does act similarly in a 
different tumor, as shown by the V600E BRAF mutants 
that respond to BRAF inhibitors in 80% of melanomas but 
only in 5% of colon cancers [90-92]. These observations 
strongly reinforce the need of an appropriate target 
validation in the context to be treated. To this purpose, 
the use of Patients-derived-xenografts (PDX) has been 
very helpful in different tumor types [93]. Tumor surgical 
specimens directly transferred in mice, in fact, conserve 
the inter-individual diversity and the genetic heterogeneity 
typical of the tumors of origin. Thus, different therapeutic 
approaches can be tested at the same time in preclinical 
proof-of concepts trials on cohorts of mice. The system, 
thus, combines the flexibility of preclinical analysis 
with the informative value of population-based studies. 
Different groups are currently generating platforms 
of gastric PDXs [94, 95] and it is very likely that the 
data derived by the preclinical work in this system will 
influence future trials. 
Another issue of targeted therapies in gastric 
cancer is represented by the high degree of intra-tumor 
heterogeneity frequently displayed by these tumors. This 
was clearly shown, for example, in HER2 [96] and MET 
expression [52]. Genetic and molecular heterogeneity 
can be observed not only inside the tumor, but also at 
metastatic sites [52], suggesting that an accurate molecular 
diagnosis should be more and more implemented with 
liquid biopsy strategies. Ideally, the problem of intra-
tumor heterogeneity could be overcome targeting “trunk” 
mutations, that is somatic alterations driving tumor 
growth, already present in early clonal progenitors and 
ubiquitously present at all sites of disease [97]. However, 
at present, no trunk mutations have been identified in 
gastric cancer.
Finally, a new prospective is given by the use of 
immunotherapy. The interesting results recently obtained 
with the treatment of gastric cancer patients with anti 
PDL-1 antibodies suggest the therapeutic potential of this 
approach [82]. Nevertheless, the evaluation of the activity 
of these drugs in specific molecular subtypes is worthy. 
In particular, it will be very interesting to investigate if 
immunotherapies are effective in tumors of the EBV 
subtype, showing traits of immune system activation, 
or in those of the MSI subtype, characterized by a high 
mutational load and a wide spectrum of neo-antigens. 
To conclude, we have probably reached a point 
where the development of targeted therapies in gastric 
cancer is at a turn. The possibility to combine molecular 
data, to perform pre-clinical trials on patient-derived 
material and to design “proof of concept” clinical trials 
can drive us to a real improvement of the treatment of 
gastric cancer patients. 
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